| 000 | 03111nam a2200457 i 4500 | ||
|---|---|---|---|
| 999 |
_c362907 _d362907 _x1 |
||
| 001 | 362907 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230221040153.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 210930s2021 sz | o |||| 0|eng d | ||
| 020 | _a9783030740283 | ||
| 024 | 7 |
_a10.1007/978-3-030-74028-3 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC280.L8 _b2021 EB |
|
| 245 | 0 | 0 |
_aLung Cancer : _bNew Understandings and Therapies _cedited by Anne C. Chiang, Roy S. Herbst |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2021 |
|
| 300 |
_a1 recurso en línea (VI, 264 páginas) _b17 ilustraciones, 16 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 490 | 0 |
_aCurrent Cancer Research _x2199-2592 |
|
| 505 | 0 | _aTumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index. | |
| 520 | _aLung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement. | ||
| 988 | _aSpringer_Medicine_2021 | ||
| 650 | 7 |
_2embne _9168954 _aPulmones _xCáncer |
|
| 650 | 7 |
_2embne _9182523 _aCáncer _xInvestigación |
|
| 700 | 1 |
_aChiang, Anne C. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 700 | 1 |
_aHerbst, Roy S. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9783030740276 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030740290 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030740306 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-74028-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2022 _dz _eb _zSI |
||